Cargando…

Biomarkers for determining the prognosis in chronic myelogenous leukemia

The introduction of BCR-ABL1 tyrosine kinase inhibitors (TKIs) for treatment of chronic myelogenous leukemia in chronic phase (CML-CP) has revolutionized therapy, altering the outcome from one of shortened life expectancy to long-term survival. With over 10 years of long-term treatment with imatinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sweet, Kendra, Zhang, Ling, Pinilla-Ibarz, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3737033/ https://www.ncbi.nlm.nih.gov/pubmed/23870290 http://dx.doi.org/10.1186/1756-8722-6-54

Ejemplares similares

Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations
por: Sweet, Kendra, et al.
Publicado: (2014)

Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
por: Emole, Josephine, et al.
Publicado: (2016)

Role of ofatumumab in treatment of chronic lymphocytic leukemia
por: Veliz, Marays, et al.
Publicado: (2011)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?
por: Gamal, Wael, et al.
Publicado: (2022)

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned
por: Pinilla-Ibarz, Javier, et al.
Publicado: (2016)

Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia
por: Janani, Gopalarethinam, et al.
Publicado: (2023)

Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia
por: Chavez, Julio C, et al.
Publicado: (2013)

Chronic myelogenous leukemia in Libya
por: Mehdi, Itrat, et al.
Publicado: (2012)

Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018)

Chronic myelogenous leukemia in ulcerative colitis
por: Katsanos, Konstantinos H., et al.
Publicado: (2011)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

Atypical Presentation of Chronic Myelogenous Leukemia
por: Updyke, Katelyn Mariko, et al.
Publicado: (2017)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
por: Lee, Jae Wook, et al.
Publicado: (2011)

The choice of first-line Chronic Myelogenous Leukemia treatment
por: Fava, Carmen, et al.
Publicado: (2015)

Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach
por: Keramatinia, Aliasghar, et al.
Publicado: (2017)

Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia
por: Ross, Theodora S, et al.
Publicado: (2014)

Role of Lysophospholipid Metabolism in Chronic Myelogenous Leukemia Stem Cells
por: Naka, Kazuhito
Publicado: (2021)

Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient
por: Beaud, Jenny, et al.
Publicado: (2018)

A case report and case review: Chronic myeloid leukemia (CML) blast phase with myelomastocytic differentiation
por: Song, Jinming, et al.
Publicado: (2020)

Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
por: de Almeida Filho, T.P., et al.
Publicado: (2019)

Primary hyperparathyroidism in a case of chronic myelogenous leukemia
por: Valizadeh, Nasim, et al.
Publicado: (2013)

Activation of the hedgehog pathway in chronic myelogeneous leukemia patients
por: Long, Bing, et al.
Publicado: (2011)

Unusual T-Lymphoblastic Blast Phase of Chronic Myelogenous Leukemia
por: Xu, Jie, et al.
Publicado: (2014)

Focal lymphoblastic transformation of chronic myelogenous leukemia develops into erythroid leukemia: A case report
por: Wang, Wei, et al.
Publicado: (2023)

Circulating miRNAs can serve as potential diagnostic biomarkers in chronic myelogenous leukemia patients
por: Keramati, Farid, et al.
Publicado: (2021)

Omacetaxine Mepesuccinate: A New Treatment Option for Patients With Chronic Myelogenous Leukemia
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
por: Steinbach, Alison, et al.
Publicado: (2013)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities
por: Flis, Sylwia, et al.
Publicado: (2019)

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Karp, Judith E, et al.
Publicado: (2008)

Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation()
por: Tsukamoto, Shokichi, et al.
Publicado: (2013)

Dynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia
por: Kim, Peter S., et al.
Publicado: (2008)

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
por: Xu, Zhenshu, et al.
Publicado: (2009)

Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2014)

Chronic Myelogenous Leukemia Presenting with Facial Nerve Palsy in an Infant
por: KHAJEH, Ali, et al.
Publicado: (2018)

Acute appendicitis revealing a diagnosis of chronic myelogenous leukemia
por: Ahmad, Rita, et al.
Publicado: (2021)

Inflammation Promotes Oxidative and Nitrosative Stress in Chronic Myelogenous Leukemia
por: Đikić, Dragoslava, et al.
Publicado: (2022)

Management of chronic myelogenous leukemia with COVID-19 and hepatitis B
por: Yu, Tian, et al.
Publicado: (2023)

LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia
por: Hu, Tingting, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ccjcvltbpr5o9ec9bsjoleni3n